

Benoît Brethon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2712345/publications.pdf>

Version: 2024-02-01

29
papers

518
citations

933447

10
h-index

677142

22
g-index

31
all docs

31
docs citations

31
times ranked

913
citing authors

#	ARTICLE	IF	CITATIONS
1	Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis. <i>Blood Advances</i> , 2022, 6, 1004-1014.	5.2	22
2	Isavuconazole Treatment for Invasive Fungal Infections in Pediatric Patients. <i>Pharmaceuticals</i> , 2022, 15, 375.	3.8	7
3	Impact of COVID-19 on cancer care: A survey from the French Society of Pediatric Oncology (SFCE). <i>Pediatric Blood and Cancer</i> , 2021, 68, e28554.	1.5	8
4	A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study). <i>Blood</i> , 2021, 137, 1582-1590.	1.4	48
5	Case Report: Targeting 2 Antigens as a Promising Strategy in Mixed Phenotype Acute Leukemia: Combination of Blinatumomab With Gemtuzumab Ozogamicin in an Infant With a KMT2A-Rearranged Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 637951.	2.8	17
6	Clinical Implications of Minimal Residual Disease Detection in Infants With <i>KMT2A</i> -Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol. <i>Journal of Clinical Oncology</i> , 2021, 39, 652-662.	1.6	41
7	End-of-life care in children and adolescents with cancer: perspectives from a French pediatric oncology care network. <i>Tumori</i> , 2021, , 030089162110133.	1.1	5
8	Invasive Fungal Infections in Immunocompromised Children: Novel Insight Following a National Study. <i>Journal of Pediatrics</i> , 2021, 236, 204-210.	1.8	10
9	Minimal Residual Disease and Outcome Characteristics in Infant <i>KMT2A</i> -Germline Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol. <i>Blood</i> , 2021, 138, 2383-2383.	1.4	0
10	Tolerance to arsenic trioxide combined with all-trans-retinoic acid in children with acute promyelocytic leukaemia in France. <i>British Journal of Haematology</i> , 2020, 188, 170-173.	2.5	6
11	Impact of the First Wave of COVID-19 on Pediatric Oncology and Hematology: A Report from the French Society of Pediatric Oncology. <i>Cancers</i> , 2020, 12, 3398.	3.7	26
12	Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study. <i>Blood Cancer Journal</i> , 2020, 10, 77.	6.2	65
13	COVID-19 in pediatric oncology from French pediatric oncology and hematology centers: High risk of severe forms?. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28392.	1.5	74
14	Inotuzumab ozogamicin compassionate use for French paediatric patients with relapsed or refractory CD22 positive B-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2020, 190, e53-e56.	2.5	15
15	Blinatumomab in Children with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R-ALL): Final Results of 110 Patients Treated in an Expanded Access Study (RIALTO). <i>Blood</i> , 2020, 136, 24-25.	1.4	2
16	Durable remissions in <i>TCF3-HLF</i> positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation. <i>Haematologica</i> , 2019, 104, e244-e247.	3.5	52
17	Azacitidine in Pediatric Hematologic Myeloid Malignancies: A Retrospective Study. <i>Blood</i> , 2019, 134, 5130-5130.	1.4	1
18	Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2018, 131, 289-300.	1.4	97

#	ARTICLE	IF	CITATIONS
19	High Molecular Remission Rate in Pediatric Patients (pts) with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (r/r ALL) Treated with Blinatumomab: Rialto an Open-Label, Multicenter, Expanded Access Study. <i>Blood</i> , 2018, 132, 1375-1375.	1.4	3
20	Inotuzumab Ozogamicin Compassionate Use for French Pediatric Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 5203-5203.	1.4	2
21	A Phase I Study of Clofarabine With Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (VANDEVOL Study of the French SFCE Acute Leukemia Committee). <i>Pediatric Blood and Cancer</i> , 2016, 63, 270-275.	1.5	10
22	Oncogenetic Risk Classification Based on NOTCH1/FBXW7/RAS/PTEN Mutation Profiles Improves Outcome Prediction in Pediatric T-Cell Acute Lymphoblastic Leukemia, Treated According the Fralle 2000 T Guidelines. <i>Blood</i> , 2016, 128, 1083-1083.	1.4	2
23	Safety and Efficacy of Blinatumomab Used in Children with B-Precursor Acute Lymphoblastic Leukemia (ALL) Treated in French Hematological Centers. <i>Blood</i> , 2016, 128, 5190-5190.	1.4	1
24	Immunophenotypic Profiling of Childhood B-Cell Precursor Acute Lymphoblastic Helps Identifying Genetic Subtypes, Including Recently Identified Ones. <i>Blood</i> , 2016, 128, 2910-2910.	1.4	0
25	Late Effects in Survivors of Infantile Acute Leukemia Are Less Severe Than Expected: A Study of the L.E.a Program. <i>Blood</i> , 2016, 128, 3571-3571.	1.4	0
26	Clofarabine in Combination with High-Dose Cytarabine and Liposomal Daunorubicin in Pediatric AML: Results of a Phase 1B Combination Study By the ITCC Consortium. <i>Blood</i> , 2014, 124, 989-989.	1.4	1
27	Nelarabine Alone or in Combination in High Risk Childhood / Adolescent and Young Adults (AYA) T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 3723-3723.	1.4	0
28	Safety of Clofarabine with Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (Vandevol study of the French SFCE Acute Leukemia Committee).. <i>Blood</i> , 2012, 120, 2570-2570.	1.4	0
29	Daunorubicin or Not During the Induction Treatment of Childhood Standard-Risk B-Cell Precursor Acute Lymphoblastic Leukemia (SR-BCP-ALL): The Randomized Fralle 2000-A Protocol. <i>Blood</i> , 2012, 120, 135-135.	1.4	0